Everest Medicines Limited (HKG: 1952), a China-based biopharmaceutical company, has announced that it has received market approval from the Department of Health of the Hong Kong Special Administrative Region for its antibiotic Xerava (eravacycline). The approval is for the treatment of complicated intra-abdominal infections (cIAI) in adult patients in the region.
About Xerava
Xerava (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline antibiotic of the tetracycline class. It has demonstrated broad in vitro activity against both Gram-negative and Gram-positive pathogens, including those that have acquired multidrug resistance (MDR) and are prevalent in China. Xerava is currently approved for the treatment of cIAI in the US, EU, UK, and Singapore. The drug is also under review for cIAI in Greater China, and Everest Medicines is developing it for the treatment of community-acquired bacterial pneumonia (CABP).
Licensing and Development
Xerava was licensed from Tetraphase Pharmaceuticals, a wholly-owned subsidiary of La Jolla Pharmaceutical Company. The approval in Hong Kong marks another significant milestone in the global development and commercialization of this important antibiotic, further expanding its reach to patients in need.-Fineline Info & Tech
